Development of a New Combination Compound (Cyclopamine) Isolated from Veratrum californicum and 5-FU Acting as Anti-invasive and Initiator of Intrinsic Apoptosis Mechanism against Aggressive Type Colorectal Cancer Cells
DOI:
https://doi.org/10.48048/tis.2022.2159Keywords:
Cyclopamine, Cell viability, Colorectal cancer, 5-fluorouracil, invasiveAbstract
Characteristics of programmed cell death are generally regarded as defined by cell outgrowth or cellular aging and distinct morphological characteristics featuring nuclear condensation and formation of apoptotic bodies. Apoptosis is considered to have a function at cellular level and is essential to long-lived cell differentiation undergoing senescence and apoptosis. Inappropriate apoptosis is a factor that results in serious conditions, causing multiple disease progression as well as cancer. The ability to modulate the life or death of a cancer cell is recognized for its immense therapeutic potential. Therefore, the research findings that are focused on the elucidation of a newly synthesized drug or drug derived from a natural plant to stop the cell cycle mechanism and signaling pathways that control cell cycle arrest and apoptosis are considered necessary. The field research of apoptosis is moving forward at a rapid rate. The goal of this paper is to investigate a natural active constituent, which is simply identified as “a drug for near future co-chemotherapy”, as well as to explore the ability to activate the apoptotic pathway. Our results demonstrated that cyclopamine provides an excellent anti-tumor activity and changing of the morphology of cancerous cells in the early and late phases of apoptosis, indicating that cyclopamine has the potential to chemosensitize SW-620 cancer cells to 5-FU based chemotherapy, which may be useful for the treatment of colorectal cancer and the fight to overcome drug resistance in advanced colorectal cancer.
Downloads
Metrics
References
H Brenner, M Kloor and CP Pox. Colorectal cancer. Lancet 2014; 383, 1490-502.
DB Longley and PG Johnston. Molecular mechanisms of drug resistance. J. Pathol. 2005; 205, 275-92.
JL Grem. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 2000; 18, 299-313.
DB Longley, DP Harkin and PG Johnston. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003; 3, 330-8.
S Giacchetti, B Perpoint, R Zidani, NL Bail, R Faggiuolo, C Focan, P Chollet, JF Llory, Y Letourneau, B Coudert, F Bertheaut-Cvitkovic, D Larregain-Fournier, AL Rol, S Walter, R Adam, JL Misset and F Lévi. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000; 18, 136-47.
JY Douillard, D Cunningham, AD Roth, M Navarro, RD James, P Karasek, P Jandik, T Iveson, J Carmichael, M Alakl, G Gruia, L Awad and P Rougier. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355, 1041-7.
FM Santandreu, A Valle, J Oliver and P Roca. Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol. Biochem. 2011; 28, 219-28.
MW Turner, R Cruz, J Mattos, N Baughman, J Elwell, J Fothergill, A Nielsen, J Brookhouse, A Bartlett, P Malek, X Pu, MD King and OM McDougal. Cyclopamine bioactivity by extraction method from Veratrum californicum. Bioorg. Med. Chem. 2016; 24, 3752-7.
J Taipale, JK Chen, MK Cooper, B Wang, RK Mann, L Milenkovic, MP Scott and PA Beachy. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406, 1005-9.
H Ma, HQ Li and X Zhang. Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy. Curr. Top. Med. Chem. 2013; 13, 2208-15.
P Heretsch, L Tzagkaroulaki and A Giannis. Cyclopamine and hedgehog signaling: Chemistry, biology, medical perspectives. Angew. Chem. Int. Ed. Engl. 2010; 49, 3418-27.
Z Shafaee, H Schmidt, W Du, M Posner and R Weichselbaum. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother. Pharmacol. 2006; 58, 765-70.
S Mukherjee, N Frolova, A Sadlonova, Z Novak, A Steg, GP Page, DR Welch, SM Lobo-Ruppert, JM Ruppert, MR Johnson and AR Frost. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol. Ther. 2006; 5, 674-83.
M Mimeault, SL Johansson, JP Henichart, P Depreux and SK Batra. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther. 2010; 9, 617-30.
S Eimer, F Dugay, K Airiau, T Avril, V Quillien, MA Belaud-Rotureau and F Belloc. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro. Oncol. 2012; 14, 1441-51.
SA Almawash, G Mondal and RI Mahato. Coadministration of polymeric conjugates of docetaxel and cyclopamine synergistically inhibits orthotopic pancreatic cancer growth and metastasis. Pharm. Res. 2018; 35, 17.
ST Lee, KD Welch, KE Panter, DR Gardner, M Garrossian and CW Chang. Cyclopamine: From cyclops lambs to cancer treatment. J. Agr. Food Chem. 2014; 62, 7355-62.
T Kawahara, N Kawaguchi-Ihara, Y Okuhashi, M Itoh, N Nara and S Tohda. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res. 2009; 29, 4629-32.
YZ Feng, T Shiozawa, T Miyamoto, H Kashima, M Kurai, A Suzuki, J Ying-Song and I Konishi. Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin. Cancer Res. 2007; 13, 1389-98.
J Warzecha, L Bonke, U Koehl, D Munkelt, S Gottig, D Percic, M Arabmotlagh and A Kurth. The hedgehog inhibitor cyclopamine induces apoptosis in leukemic cells in vitro. Leuk Lymphoma 2008; 49, 2383-6.
B Zhang, H Wang, T Jiang, K Jin, Z Luo, W Shi, H Mei, H Wang, Y Hu, Z Pang and X Jiang. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer. J. Drug Target. 2018; 26, 913-9.
D Qualtrough, P Rees, B Speight, AC Williams and C Paraskeva. The hedgehog inhibitor cyclopamine reduces beta-catenin-Tcf transcriptional activity, induces E-cadherin expression, and reduces invasion in colorectal cancer cells. Cancers (Basel) 2015; 7, 1885-99.
J Che, FZ Zhang, CQ Zhao, XD Hu and SJ Fan. Cyclopamine is a novel hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells. Oncol. Lett. 2013; 5, 1417-21.
S Elmore. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007; 35, 495-516.
R Jan and GE Chaudhry. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv. Pharm. Bull. 2019; 9, 205-18.
K Fernald and M Kurokawa. Evading apoptosis in cancer. Trends Cell Biol. 2013; 23, 620-33.
L Portt, G Norman, C Clapp, M Greenwood and MT Greenwood. Anti-apoptosis and cell survival: A review. Biochim. Biophys. Acta 2011; 1813, 238-59.
J Plati, O Bucur and R Khosravi-Far. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J. Cell Biochem. 2008; 104, 1124-49.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
